Multicenter database for pancreatic solid pseudopapillary neoplasm

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational multicenter effort will systematically collect real-world clinical, pathological, imaging, surgical, and follow-up data from patients with pathologically or cytologically confirmed pancreatic solid pseudopapillary neoplasm (SPN). Patients of any age and gender who meet diagnostic criteria and agree to follow-up are eligible, with Shanghai Cancer Center serving as the lead site for data contribution. The database will aggregate information on demographics, tumor characteristics, treatments (including surgery), and outcomes to generate real-world evidence for clinical and translational research. Analyses will examine natural history, prognostic features, patterns of care, and factors linked to recurrence or metastasis to inform management and future studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* No restrictions on age, gender, or performance status;
* Pathologically/cytologically confirmed SPN;
* Compliance with follow-up requirements;

Exclusion Criteria:

* Non-neoplastic pancreatic lesions;
* Non-pancreatic primary tumors;
* Non-compliance with follow-up;

Where it's running

• Shanghai Cancer Center
  Shanghai, Special Administrative Region, China Recruiting

Study contacts

• Principal investigator: Guopei Luo — Shanghai Cancer Center
• Study coordinator: Huanyu Xia, MD
• Email: xiahuanyu@fudanpci.org
• Phone: +86 2164175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tegavivint treatment for recurrent or refractory solid tumors in children

  This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.

  Recruiting at 19 sites Phase 1/2 Children's Oncology Group · Birmingham, Alabama and 20 other locations · NCT04851119

• Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice

  This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.

  Recruiting Fudan University · Shanghai, Jingan · NCT07923812

• ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases

  This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07917104

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.